Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) has provided an announcement.
Venus Medtech (Hangzhou) Inc. reported its unaudited consolidated interim results for the first half of 2025, showing a decrease in revenue by 18.9% compared to the same period in 2024. Despite a reduction in losses before tax by 35.1%, the company continues to face challenges with a loss of RMB 134,772,000 for the period, highlighting ongoing financial pressures and the need for strategic adjustments to improve profitability.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a joint stock company incorporated in the People’s Republic of China, operating in the medical technology industry. The company focuses on developing and commercializing innovative medical devices, particularly in the cardiovascular sector.
Average Trading Volume: 5,359,860
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.88B
For detailed information about 2500 stock, go to TipRanks’ Stock Analysis page.